UA85500C2 - Композиция, имеющая гепатопротекторную активность и нормализующая обменные процессы - Google Patents
Композиция, имеющая гепатопротекторную активность и нормализующая обменные процессы Download PDFInfo
- Publication number
- UA85500C2 UA85500C2 UAA200605629A UAA200605629A UA85500C2 UA 85500 C2 UA85500 C2 UA 85500C2 UA A200605629 A UAA200605629 A UA A200605629A UA A200605629 A UAA200605629 A UA A200605629A UA 85500 C2 UA85500 C2 UA 85500C2
- Authority
- UA
- Ukraine
- Prior art keywords
- phospholipid
- mass
- pharmaceutical composition
- composition according
- shell
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 128
- 230000004060 metabolic process Effects 0.000 title claims abstract description 12
- 230000000694 effects Effects 0.000 title abstract description 11
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 89
- 239000008188 pellet Substances 0.000 claims abstract description 50
- 150000001413 amino acids Chemical class 0.000 claims abstract description 37
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 30
- 239000008187 granular material Substances 0.000 claims abstract description 30
- 229930182817 methionine Natural products 0.000 claims abstract description 30
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000004473 Threonine Substances 0.000 claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
- 239000000945 filler Substances 0.000 claims abstract description 25
- 239000002775 capsule Substances 0.000 claims abstract description 17
- 239000000243 solution Substances 0.000 claims abstract description 12
- 239000000725 suspension Substances 0.000 claims abstract description 11
- 235000020357 syrup Nutrition 0.000 claims abstract description 11
- 239000006188 syrup Substances 0.000 claims abstract description 11
- 239000007924 injection Substances 0.000 claims abstract description 10
- 238000002347 injection Methods 0.000 claims abstract description 10
- 239000003797 essential amino acid Substances 0.000 claims abstract description 9
- 235000020776 essential amino acid Nutrition 0.000 claims abstract description 9
- 239000003826 tablet Substances 0.000 claims abstract description 9
- 229920000642 polymer Polymers 0.000 claims description 51
- 235000010469 Glycine max Nutrition 0.000 claims description 15
- 102000002322 Egg Proteins Human genes 0.000 claims description 14
- 108010000912 Egg Proteins Proteins 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 14
- 235000013345 egg yolk Nutrition 0.000 claims description 14
- 210000002969 egg yolk Anatomy 0.000 claims description 14
- 230000002443 hepatoprotective effect Effects 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 238000011287 therapeutic dose Methods 0.000 claims description 6
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 3
- -1 for example Substances 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000022558 protein metabolic process Effects 0.000 abstract description 9
- 230000023852 carbohydrate metabolic process Effects 0.000 abstract description 7
- 235000021256 carbohydrate metabolism Nutrition 0.000 abstract description 7
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 208000019423 liver disease Diseases 0.000 abstract description 4
- 238000010606 normalization Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 238000005303 weighing Methods 0.000 description 50
- 241000700159 Rattus Species 0.000 description 31
- 210000002966 serum Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 11
- 244000068988 Glycine max Species 0.000 description 10
- 235000013399 edible fruits Nutrition 0.000 description 10
- 238000010171 animal model Methods 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 7
- 239000008116 calcium stearate Substances 0.000 description 7
- 235000013539 calcium stearate Nutrition 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000000454 talc Substances 0.000 description 7
- 229910052623 talc Inorganic materials 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 4
- 229940001584 sodium metabisulfite Drugs 0.000 description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 239000001685 glycyrrhizic acid Substances 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 150000002632 lipids Chemical group 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000037023 motor activity Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000001995 reticulocyte Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000020374 simple syrup Nutrition 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000002990 parathyroid gland Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008023 pharmaceutical filler Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000021092 sugar substitutes Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000003923 scrap metal Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к области медицины и касается создания фармацевтической композиции на основе фосфолипида, имеющего гепатопротекторную активность, нормализующего обменные процессы, которая может быть использована при изготовлении лечебного средства в виде таблеток, гранул, пелет, капсул, растворов для инъекций, сиропа, суспензий.Композиция, содержит фосфолипид, незаменимую аминокислоту, в частности метионин или треонин, и наполнитель, при суммарном содержимом фосфолипида и аминокислоты 15-80 % и их массовом соотношении 2:1.Предложенная фармацевтическая композиция имеет выраженную гепатопротекторную активность и позволяет нормализовать жировой, белковый и углеводный обмены, а также расширяет арсенал лечебных средств для лечения заболеваний печени в виде разных лекарственных форм.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA200605629A UA85500C2 (ru) | 2006-05-23 | 2006-05-23 | Композиция, имеющая гепатопротекторную активность и нормализующая обменные процессы |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA200605629A UA85500C2 (ru) | 2006-05-23 | 2006-05-23 | Композиция, имеющая гепатопротекторную активность и нормализующая обменные процессы |
Publications (1)
Publication Number | Publication Date |
---|---|
UA85500C2 true UA85500C2 (ru) | 2009-01-26 |
Family
ID=50556637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200605629A UA85500C2 (ru) | 2006-05-23 | 2006-05-23 | Композиция, имеющая гепатопротекторную активность и нормализующая обменные процессы |
Country Status (1)
Country | Link |
---|---|
UA (1) | UA85500C2 (ru) |
-
2006
- 2006-05-23 UA UAA200605629A patent/UA85500C2/ru unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kendall | THE ISOLATION IN CRYSTALLINE FORM OF THE COM-POUND CONTAINING IODIN WHICH OCCURS IN THE THYROID; ITS CHEMICAL NATURE AND PHYSIOLOGICAL ACTIVITY | |
CN102935222B (zh) | 三价铁卟啉短肽化合物在抗2型糖尿病药物制备中的用途 | |
Prasad | Zinc in human nutrition | |
WO1995022336A1 (fr) | Agent immunomodulateur et reducteur du dysfonctionnement du systeme de regulation de la propagation de cellules tissulaires | |
RU2283114C1 (ru) | Композиция, обладающая гепатопротекторной активностью и нормализующая обменные процессы | |
RU2504222C2 (ru) | Пищевой продукт, обладающий лечебно-профилактическими свойствами | |
JPH05500655A (ja) | 異化性腸管関連疾患および宿主防衛機構障害の治療用医薬組成物 | |
EP2656853A1 (en) | Method for treating acute cerebral and spinal blood flow disorders of an ischaemic or haemorrhagic nature | |
UA85500C2 (ru) | Композиция, имеющая гепатопротекторную активность и нормализующая обменные процессы | |
Dubin | Physiology of the phenols | |
Drummond | A study of the water-soluble accessory growth promoting substance in yeast. I | |
EP0389667A2 (en) | Use of lecithin to restore olfaction and taste | |
RU2112504C1 (ru) | Средство для лечения заболеваний предстательной железы "витапрост" | |
UA58565C2 (ru) | Инъекционный лекарственный препарат "цитофлавин", обладающий цитопротекторным действием | |
RU2228739C1 (ru) | Препарат для адаптогенной терапии (варианты) и способ его изготовления | |
RU2390348C1 (ru) | Средство "стабинорм" для лечения синдрома хронической усталости | |
RU2763761C1 (ru) | Гепатопротекторное гуминовое средство | |
McClure | Metabolism in a Case of Hemochromatosis | |
CN109223766A (zh) | 改善人体微循环提高人体免疫力的组合物和制备工艺 | |
Rizaeva et al. | Pre-clinical study of acute toxicity of biologically active additive" ascorbic-drop". | |
Lannek | Toxicity of Halogenated Oxyquinolines in Dogs. A Clinical Study: II. History, Symptoms, Laboratory Findings, Therapy, and Follow-Up | |
Bodansky | The effect of compounds related to hydrazine in producing anhydremia and experimental anemia | |
RU2275928C2 (ru) | Фармацевтическая композиция для внутреннего применения, обладающая иммунотропной и адаптогенной активностями | |
RU2418579C1 (ru) | Иммуностимулирующий препарат для нормализации обмена селена и коррекции стрессовых состояний для сельскохозяйственных животных | |
Hanford | A study of the physiological action and toxicology of caesium chloride |